Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Leissring, Malcolm A ^a,b,c   Malito, Enrico ^d   Hedouin, Sabrine ^a   Reinstatler, Lael ^a   Sahara, Tomoko ^a   Abdul Hay, Samer O ^a   Choudhry, Shakeel ^a   Maharvi, Ghulam M ^a   Fauq, Abdul H ^a   Huzarska, Malwina ^b   May, Philip S ^b   Choi, Sungwoon ^e   Logan, Todd P ^c   Turk, Benjamin E ^f   Cantley, Lewis C ^c   Manolopoulou, Marika ^d   Tang, Wei Jen ^d   Stein, Ross L ^e   Cuny, Gregory D ^e   Selkoe, Dennis J ^c  

^a MAYO CLINIC   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; INSULINASE; INSULINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ANALYSIS; ENZYME DEGRADATION; HUMAN; HUMAN CELL; IC 50; INSULIN DEGRADATION; PHARMACOLOGICAL BLOCKING;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; EXTRACELLULAR SPACE; HELA CELLS; HUMANS; INSULIN; INSULYSIN; MODELS, MOLECULAR; PEPTIDE LIBRARY; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 77956274306     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010504     Document Type: Article

References (50)

1. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177: 125-134.
2. Messier C, Teutenberg K (2005) The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 12: 311-328.
3. Duckworth WC, Kitabchi AE (1981) Insulin metabolism and degradation. Endocr Rev 2: 210-233.
4. Brange J, Langkjoer L (1993) Insulin structure and stability. Pharm Biotechnol 5: 315-350.
5. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, et al. (2003) Insulindegrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100: 4162-4167.
6. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19: 608-624.
7. Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292: 11-17.
8. Becker AB, Roth RA (1992) An unusual active site identified in a family of zinc metalloendopeptidases. Proc Natl Acad Sci U S A 89: 3835-3839.
9. Shen Y, Joachimiak A, Rosner MR, Tang W-J (2006) Structures of human insulin-degrading enzyme reveal a new substrate mechanism. Nature 443: 870-874.
10. Manolopoulou M, Guo Q, Malito E, Schilling AB, Tang WJ (2009) Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. J Biol Chem 284: 14177-14188.
11. Malito E, Hulse RE, Tang WJ (2008) Amyloid beta-degrading cryptidases: insulin-degrading enzyme, presequence peptidase, and neprilysin. Cell Mol Life Sci 65: 2574-2585.
12. Giugliano D, Standl E, Vilsboll T, Betteridge J, Bonadonna R, et al. (2009) Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? Acta Diabetol 46: 173-181.
13. Mirsky IA (1957) Insulinase, insulinase-inhibitors, and diabetes mellitus. Recent Prog Horm Res 13: 429-465; discussion 465-471.
14. Mirsky IA, Broth-Kahn RH (1949) The inactivation of insulin by tissue extracts. I. The distribution and properties of insulin inactivating extracts (insulinase). Arch Biochem 20: 1-9.
15. Mirsky IA, Perisutti G (1955) Effect of insulinase-inhibitor on hypoglycemic action of insulin. Science 122: 559-560.
16. Leissring MA, Selkoe DJ (2006) Enzyme target to latch on to. Nature 443: 761-762.
17. Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, et al. (2003) Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem 278: 37314-37320.
18. Neant-Fery M, Garcia-Ordonez RD, Logan TP, Selkoe DJ, Li L, et al. (2008) Molecular basis for the thiol sensitivity of insulin-degrading enzyme. Proc Natl Acad Sci U S A 105: 9582-9587.
19. Tong M, Ding Y, Tai HH (2006) Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol 72: 701-709.
20. Nishino N, Powers JC (1978) Peptide hydroxamic acids as inhibitors of thermolysin. Biochemistry 17: 2846-2850.
21. Powers JC, Odake S, Oleksyszyn J, Hori H, Ueda T, et al. (1993) Proteases- structures, mechanism and inhibitors. Agents Actions Suppl 42: 3-18.
22. Turk BE, Huang LL, Piro ET, Cantley LC (2001) Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 19: 661-667.
23. Cabrol C, Huzarska MA, Dinolfo C, Rodriguez MC, Reinstatler L, et al. (2009) Small-molecule activators of insulin-degrading enzyme discovered through highthroughput compound screening. PLoS ONE 4: e5274.
24. Zhao J, Li L, Leissring MA (2009) Insulin-degrading enzyme is exported via an unconventional protein secretion pathway. Mol Neurodegener 4: 4.
25. Duckworth WC (1988) Insulin degradation: mechanisms, products, and significance. Endocr Rev 9: 319-345.
26. Authier F, Metioui M, Fabrega S, Kouach M, Briand G (2002) Endosomal proteolysis of internalized insulin at the C-terminal region of the B chain by cathepsin D. J Biol Chem 277: 9437-9446.
27. Hamel FG, Mahoney MJ, Duckworth WC (1991) Degradation of intraendosomal insulin by insulin-degrading enzyme without acidification. Diabetes 40: 436-443.
28. Hentz NG, Richardson JM, Sportsman JR, Daijo J, Sittampalam GS (1997) Synthesis and characterization of insulin-fluorescein derivatives for bioanalytical applications. Anal Chem 69: 4994-5000.
29. Terris S, Steiner DF (1975) Binding and degradation of 125I-insulin by rat hepatocytes. J Biol Chem 250: 8389-8398.
30. Song ES, Juliano MA, Juliano L, Fried MG, Wagner SL, et al. (2004) ATP effects on insulin-degrading enzyme are mediated primarily through its triphosphate moiety. J Biol Chem 279: 54216-54220.
31. Im H, Manolopoulou M, Malito E, Shen Y, Zhao J, et al. (2007) Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE. J Biol Chem 282: 25453-25463.
32. Safavi A, Miller BC, Cottam L, Hersh LB (1996) Identification of gammaendorphin- generating enzyme as insulin-degrading enzyme. Biochemistry 35: 14318-14325.
33. Farris W, Leissring MA, Hemming ML, Chang AY, Selkoe DJ (2005) Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. Biochemistry 44: 6513-6525.
34. Song ES, Rodgers DW, Hersh LB (2010) A monomeric variant of insulin degrading enzyme (IDE) loses its regulatory properties. PLoS One 5: e9719.
35. Song ES, Juliano MA, Juliano L, Hersh LB (2003) Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development. J Biol Chem 278: 49789-49794.
36. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, et al. (2009) Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci.
37. Nuti E, Tuccinardi T, Rossello A (2007) Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors. Curr Pharm Des 13: 2087-2100.
38. Mirsky IA (1956) The role of insulinase and insulinase-inhibitors. Metabolism 5: 138-143.
39. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70: 440-448.
40. Garcia JV, Fenton BW, Rosner MR (1988) Isolation and characterization of an insulin-degrading enzyme from Drosophila melanogaster. Biochemistry 27: 4237-4244.
41. Becker AB, Roth RA (1995) Insulysin and pitrilysin: insulin-degrading enzymes of mammals and bacteria. Methods Enzymol 248: 693-703.
42. Malito E, Ralat LA, Manolopoulou M, Tsay JL, Wadlington NL, et al. (2008) Molecular bases for the recognition of short peptide substrates and cysteinedirected modifications of human insulin-degrading enzyme. Biochemistry 47: 12822-12834.
43. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods in Enzymology 276(Macromolecular Crystallography, Part A). pp 307-326.
44. McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
45. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, et al. (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D 58: 1948-1954.
46. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
47. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
48. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, et al. (2004) Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164: 1425-1434.
49. Seta KA, Roth RA (1997) Overexpression of insulin-degrading enzyme: cellular localization and effects on insulin signaling. Biochem Biophys Res Commun 231: 167-171.
50. DeLano WL (2002) The PyMOL Molecular Graphics System. Palo Alto CA: DeLano Scientific.